Business Wire

9UNICORNS

9.5.2022 03:32:13 CEST | Business Wire | Press release

Share
9Unicorns Sets a Benchmark for Largest Accelerator Fund for Idea & Product Stage Startups With Its Fifth Closure at $100Mn

9Unicorns, India’s leading early-to-growth stage accelerator fund, has announced the fifth closure of its maiden fund at $100 million. The fund has so far invested in 110+ idea & product startups including a few growth stage / series C players like Vedantu, ShipRocket, ShopKirana.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220507005005/en/

It plans to invest $500K to $1 million in the idea stage and, up to $2 million in high-growth stage Series C and above startups this year with a focus on DeepTech, Enterprise SaaS , Web 3.0, FinTech, Media, InsureTech, HealthTech, EduTech & D2C startups.

Commenting on the fifth close , Dr. Apoorva Ranjan Sharma, Managing Director and Founder of 9Unicorns, said, "Our unique approach to redefine idea-stage funding has led to an increased fund size with several leading LPs believing in our strategy. Besides, last year was one of the best times for the startup ecosystem with a funding rush. We invested in 101 deals in 2021 and plan to double that amount this year. We will finish deploying the fund by mid-next year , post which we plan to launch our second fund.”

Backed by global LPs, 9Unicorns’ USP lies in the fact that it allows the startups to tap into its vast Indian business communities in cities beyond the metros immediately enabling them to go pan-India. It directly allows getting early customers, distribution partnerships, cross-portfolio synergies for startups leveraging the pre-existing network of over 5500+ investors, founders, and executives in its ecosystem.

One of the portfolio and Klub Founder, Anurakt Jain, said, ‘’9Unicorns has been a key supporter from Day 0 for Klub. 9Unicorns team is more like founders turned entrepreneurs. The latest fundraise from $50M to $100M has enabled them to double down in portfolio significantly in subsequent rounds of financing. In current markets, it has become extremely crucial to have a long-term committed partner like them in any startup.”

Another portfolio founder, Dr. Arbinder Singal, a pediatric surgeon and a 2X successful entrepreneur, said, “Chemistry of 9Unicorns’ to co-invest with top Tier funds is remarkable. One of the most founder-friendly teams in the VC ecosystem. As we build fitterfly into the largest digital healthcare platform, their partnership & pace of decision making in multiple rounds is something I would always recognize as the most important quality.”

Link:

ClickThru

Social Media:

https://www.facebook.com/9UnicornsVC

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Parse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune Biology29.10.2026 13:00:00 CET | Press release

Licensable perturbation dataset to include transcriptomes and proteomic secretomes for understanding the human immune response Parse Biosciences, the leading provider of scalable and accessible single-cell sequencing and a QIAGEN company, and Nomic Bio, a leader in high throughput proteomic profiling, today announced their partnership to generate Cascade, a 100 Million cell foundational dataset to understand the human immune response. The dataset's scale and depth will give pharma partners cellular- and protein-level insight into immune biology, accelerating their ability to identify and validate new drug targets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029559438/en/ Cascade has already drawn foundational partner commitments from leading pharmaceutical and biotechnology companies, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, underscoring the demand for large-scale, multimodal immune data in drug

CSC Named Winner of the Top InfoSec Innovator Award for Most Innovative DNS Security29.10.2026 13:00:00 CET | Press release

CSC’s Subdomain Monitoring recognized for innovation in mitigating subdomain hijacking risks from dangling DNS CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and Domain Name System (DNS) threats, today announced that its Subdomain Monitoring solution took top honors for Most Innovative DNS Security in Cyber Defense Magazine’s 2026 Top InfoSec Innovator Awards. CSC introduced Subdomain Monitoring after analyzing close to half a million DNS records and finding that many companies were exposed to subdomain takeovers due to dangling DNS. CSC’s solution helps enterprises reduce this risk and secure their online ecosystems. It was the first and only technology on the market to ease the burden of tracking and maintaining DNS records and purging unused zone records to prevent subdomain hijacking. Subdomain Monitoring, powered by CSC’s one-of-a-kind DomainSecSM threat intelligence platform, alerts DNS administrators and security engineers when it

Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 12:27:00 CET | Press release

EMA has validated two marketing authorization applications from Daiichi Sankyo in the EU for single-pill triple-combinations of established lipid-lowering agents: bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin If approved, the proposed therapies could be the first oral single-pill triple-combinations for lipid-lowering in the EU, aiming to simplify treatment for patients requiring multiple lipid-lowering agents The submissions reflect the commitment of Daiichi Sankyo to addressing unmet needs in cardiovascular disease The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinu

NIQ and Google Partner to Advance Agentic Commerce29.10.2026 11:45:00 CET | Press release

Built with Google Cloud and Gemini for business, NIQ and Google commit to transforming AI-driven product discovery, availability, and measurement Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable,

TradeStation Europe Expands Options Capability, Including Extended-Hours Trading29.10.2026 11:43:00 CET | Press release

Expanded intraday and options trading capability, combined with lower options and equities commissions across the Netherlands and the EEA TradeStation Europe B.V. (“TradeStation Europe”), the recently licensed European brokerage subsidiary of TradeStation Group, Inc. (“TradeStation”), today announced a round of product updates, including extended-hours options trading, along with reduced options and equities pricing, new single-stock option spreads and expanded intraday trading to enhance the offering for retail and institutional traders across the Netherlands and the European Economic Area (EEA). Extended-hours options trading is now live. Clients can trade eligible equity options during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and an extended curb session from 4:00 p.m. to 4:15 p.m. ET. The launch follows Cboe Global Markets, Inc.’s (Cboe: CBOE) introduction of extended trading hours for options on 24 individual stocks and five ETFs, expanding access to some of the most ac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye